Drug Formulary Review Archives – April 1, 2006
April 1, 2006
View Archives Issues
-
Joint Commission looking for evaluation and action plan for USP 797
The Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL, is concerned that some hospitals are spending too much to comply with the facilities requirements of the United States Pharmacopeia (USP) Chapter <797>, Pharmaceutical Compounding: Sterile Preparations. -
Hospital undertakes review of preprinted MD orders
Hospitals need to ensure that their preprinted physician orders meet the appropriate standards for both safety and clinical standards. A multidisciplinary team at one hospital reviewed more than 450 of its existing preprinted orders and found that many fell short. -
Learn how to get around rebound headache
Giving preventive medications to a patient who is overusing acute medication for headache may be a waste of time, according to a presenter at the American Society of Health-System Pharmacists Midyear Clinical Meeting in December. -
Abstracts highlight drug information, NICU benefits
Heres a snapshot of two Professional Posters presentation abstracts from the American Society of Health-System Pharmacists Midyear Clinical Meeting in December. -
Research News
Health care practitioners may currently favor the use of corticosteroids in the intensive care unit (ICU), especially in the setting of sepsis and relative adrenal insufficiency. -
News Briefs
Steroids taken with protease inhibitors linked to complications; HHS agencies announce initiative to improve cancer therapy; Bayer, FDA warn of administration errors for nimodipine (Nimotop); Hypoglycemia, hyperglycemia linked to gatifloxacin (Tequin) use; Bosentan label revised to include liver function monitoring; Study of natalizumab-treated patients shows no new PML cases -
New FDA Approvals
These drugs were recently approved by the FDA: Anidulafungin (Eraxis) by Pfizer. The FDA has approved anidulafungin (Eraxis) to treat certain infections caused by Candida, a yeast-like fungus that can cause serious infections in hospitalized patients or patients with compromised immune systems. -
Drug Criteria & Outcomes: Exenatide (Byetta) Drug Evaluation
Trial 1: Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 2004;27:2,628-2,635.